Financial Counselors Inc Ironwood Pharmaceuticals Inc Transaction History

Financial Counselors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	SELL	$11.05 - $12.72 $117,793 - $135,595	-10,660 Closed	0 $0
Q1 2022 Apr 28, 2022	BUY	$10.61 - $12.88 $6,259 - $7,599	590 Added 5.86%	10,660 $134,000
Q4 2021 Feb 10, 2022	BUY	$10.86 - $13.95 $109,360 - $140,476	10,070 New	10,070 $117,000
Q1 2021 Apr 29, 2021	SELL	$9.04 - $11.86 $127,463 - $167,226	-14,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.99 - $10.74 $15,283 - $18,258	1,700 Added 13.71%	14,100 $127,000
Q2 2020 Aug 07, 2020	SELL	$9.14 - $11.97 $91,582 - $119,939	-10,020 Reduced 44.69%	12,400 $128,000
Q1 2020 Apr 23, 2020	BUY	$8.58 - $14.01 $46,846 - $76,494	5,460 Added 32.19%	22,420 $226,000
Q4 2019 Jan 31, 2020	BUY	$8.22 - $14.0 $3,288 - $5,600	400 Added 2.42%	16,960 $226,000
Q3 2019 Nov 08, 2019	BUY	$8.59 - $10.96 $5,583 - $7,124	650 Added 4.09%	16,560 $142,000
Q2 2019 Aug 14, 2019	BUY	$9.8 - $12.89 $7,938 - $10,440	810 Added 5.36%	15,910 $174,000
Q1 2019 May 10, 2019	BUY	$8.27 - $12.73 $124,877 - $192,223	15,100 New	15,100 $204,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $539M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Financial Counselors Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Counselors Inc with notifications on news.